| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
91,010,000 |
| Market
Cap: |
102.84(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3801 - $19.19 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 6.8 |
| Insider 6 Months : 6.8 |
| Insider 3/6 Months : 13.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile FibroGen is a biopharmaceutical company that developes and commercializes a pipeline of therapeutics. Co. applies its capability in hypoxia-inducible factor (HIF) biology and connective tissue growth factor (CTGF) biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, Co.'s main product, is an inhibitor of HIF-prolyl hydroxylase activity that acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. Pamrevlumab is Co.'s human monoclonal antibody that inhibits the activity of CTGF for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer, and Duchenne muscular dystroph.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
50,000 |
50,000 |
50,000 |
50,000 |
| Total Buy Value |
$95,470 |
$95,470 |
$95,470 |
$95,470 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
89,840 |
259,386 |
| Total Sell Value |
$0 |
$0 |
$1,433,580 |
$4,794,856 |
| Total People Sold |
0 |
0 |
12 |
12 |
| Total Sell Transactions |
0 |
0 |
21 |
48 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Controneo Pat |
SVP, Finance and CFO |
• – – |
2021-06-15 |
4 |
AS |
$25.62 |
$103,838 |
D/D |
(4,053) |
276,677 |
|
-58% |
|
| Controneo Pat |
SVP, Finance and CFO |
• – – |
2021-06-07 |
4 |
D |
$22.90 |
$49,029 |
D/D |
(2,141) |
280,730 |
|
- |
|
| Chung Christine |
SVP, China Operations |
• – – |
2021-06-07 |
4 |
D |
$22.90 |
$46,487 |
D/D |
(2,030) |
165,251 |
|
- |
|
| Edwards Jeffrey L |
Director |
– • – |
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,700 |
17,800 |
|
- |
|
| Henderson Jeffrey William |
Director |
– • – |
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,700 |
17,800 |
|
- |
|
| Lema Gerald |
Director |
– • – |
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,700 |
9,400 |
|
- |
|
| Brennan Aoife |
Director |
– • – |
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,700 |
8,614 |
|
- |
|
| Ho Maykin |
Director |
– • – |
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,700 |
15,955 |
|
- |
|
| Kearns Thomas F Jr |
Director |
– • – |
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,700 |
52,864 |
|
- |
|
| Riggs Rory B |
Director |
– • – |
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,700 |
395,750 |
|
- |
|
| Kurkijarvi Kalevi |
Director |
– • – |
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,700 |
37,800 |
|
- |
|
| Schoeneck James A |
Director |
– • – |
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,700 |
14,100 |
|
- |
|
| Blaug Suzanne |
Director |
– • – |
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,700 |
14,048 |
|
- |
|
| Cravatt Benjamin |
Director |
– • – |
2021-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,700 |
8,614 |
|
- |
|
| Kearns Thomas F Jr |
Director |
– • – |
2021-03-11 |
4 |
S |
$35.02 |
$630,360 |
D/D |
(18,000) |
148,164 |
|
60% |
|
| Kearns Thomas F Jr |
Director |
– • – |
2021-03-11 |
4 |
OE |
$3.50 |
$63,000 |
D/D |
18,000 |
166,164 |
|
- |
|
| Kouchakji Elias |
SVP, Clinical Dev, Drug Safety |
• – – |
2021-03-08 |
4 |
D |
$33.37 |
$174,225 |
D/D |
(5,221) |
147,346 |
|
- |
|
| Controneo Pat |
SVP, Finance and CFO |
• – – |
2021-03-08 |
4 |
D |
$33.37 |
$188,774 |
D/D |
(5,657) |
282,187 |
|
- |
|
| Chung Christine |
SVP, China Operations |
• – – |
2021-03-08 |
4 |
D |
$33.37 |
$189,508 |
D/D |
(5,679) |
166,597 |
|
- |
|
| Chung Christine |
SVP, China Operations |
• – – |
2021-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
21,700 |
172,276 |
|
- |
|
| Conterno Enrique A |
Chief Executive Officer |
• • – |
2021-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
82,000 |
137,273 |
|
- |
|
| Kouchakji Elias |
SVP, Clinical Dev, Drug Safety |
• – – |
2021-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
20,800 |
152,567 |
|
- |
|
| Wettig Thane |
Chief Commercial Officer |
• – – |
2021-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
16,500 |
47,150 |
|
- |
|
| Controneo Pat |
SVP, Finance and CFO |
• – – |
2021-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
21,700 |
287,844 |
|
- |
|
| Kurkijarvi Kalevi |
Director |
– • – |
2021-02-17 |
4 |
AS |
$52.31 |
$314,383 |
D/D |
(6,000) |
33,100 |
|
-48% |
|
1240 Records found
|
|
Page 7 of 50 |
|
|
0.04 (3.42%) 
